Publications by authors named "N V Mazur"
From setbacks to success: lessons from the journey of RSV vaccine development.
Ther Adv Vaccines Immunother
December 2024
Respiratory syncytial virus (RSV) causes high worldwide infant mortality, as well as a high disease burden in the elderly. Efforts in vaccine development over the past 60 years have recently delivered three approved vaccines and two monoclonal antibodies (mAbs). Looking back at the eventful history of RSV vaccine development, several factors can be identified that have hampered the developmental pathway, including the occurrence of enhanced RSV disease (ERD) in the first vaccine attempt and the difficulty in characterizing and stabilizing the pre-fusion F protein as a vaccine target.
View Article and Find Full Text PDFObjectives: The aim of this article is to introduce the Polish adaptation of the Developmental Crisis Questionnaire (DCQ-12). In Poland, there is currently no tool for measuring the quarterlife crisis, hindering empirical exploration and cognitive understanding of this phenomenon. The DCQ-12, developed by Petrov and colleagues, serves as an age-independent measure of adult developmental crisis for research and applied purposes.
View Article and Find Full Text PDFArticle Synopsis
- RSV is a significant cause of infant mortality and poses health risks for older adults, prompting the development of various vaccines and treatments, including a protein-based maternal vaccine and monoclonal antibodies (mAb) specifically for infants.* -
- High-income countries have seen public health benefits from using nirsevimab, and several vaccines for older adults have also been approved, with ongoing clinical trials for multiple vaccine types targeting different age groups.* -
- There's a need to address disparities in vaccine access, especially in low- and middle-income countries, with plans to advance RSV vaccination efforts globally in the near future.*
The global burden of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in young children is high. The RSV prevention strategies approved in 2023 will be essential to lowering the global disease burden. In this Series paper, we describe clinical presentation, burden of disease, hospital management, emerging therapies, and targeted prevention focusing on developments and groundbreaking publications for RSV.
View Article and Find Full Text PDF